دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Racial disparities in cancer care: can we close the gap?
doi : 10.1016/S1470-2045(21)00669-0
Volume 22, Issue 12, December 2021, Page 1643
Oligometastatic renal cell carcinoma: radiotherapy as a new standard of care?
NicolasMagnéabcIgorLatorzeffcd
doi : 10.1016/S1470-2045(21)00665-3
Volume 22, Issue 12, December 2021, Pages 1644-1645
Overall survival results from the NETTER-1 trial in neuroendocrine tumours: an important milestone
IreneVirgolinia
doi : 10.1016/S1470-2045(21)00593-3
Volume 22, Issue 12, December 2021, Pages 1645-1646
ALK inhibitors for ALK-altered paediatric malignancies
LaurenceBrugieresaZeinabAfifybEricLowec
doi : 10.1016/S1470-2045(21)00608-2
Volume 22, Issue 12, December 2021, Pages 1646-1648
Daytime versus evening infusions of immune checkpoint inhibitors
FrancisLéviabc
doi : 10.1016/S1470-2045(21)00607-0
Volume 22, Issue 12, December 2021, Pages 1648-1650
Educational attainment in displaced children with cancer
CarleneWilsonabcAmanda DHutchinsond
doi : 10.1016/S1470-2045(21)00653-7
Volume 22, Issue 12, December 2021, Pages 1650-1652
Global cancer research in the post-pandemic world
DeborahMukherjiaRaul HernandoMurillobMiekeVan HemelrijckcVernaVanderpuyeeOmarShamiehfJulieTorodedC SPrameshgAasimYusufhChris MBoothiAjayAggarwaljRichardSullivandCOVID-19 and Cancer Task Force
doi : 10.1016/S1470-2045(21)00602-1
Volume 22, Issue 12, December 2021, Pages 1652-1654
Mental health care for Filipino patients with cancer
Michelle Ann BEalaaKatherine DonatelaManlongatbEdward ChristopherDeecRonnie EBaticulondJohanna Patricia ACanale
doi : 10.1016/S1470-2045(21)00570-2
Volume 22, Issue 12, December 2021, Page e531
RAMES study: is there really a role for VEGF inhibition in mesothelioma?
CamilloPortaaValerioNardonebSteven GGraycPierpaoloCorrealedLucianoMuttie
doi : 10.1016/S1470-2045(21)00640-9
Volume 22, Issue 12, December 2021, Page e532
RAMES study: is there really a role for VEGF inhibition in mesothelioma? – Authors' reply
Paolo AndreaZucaliabCarminePintocGiovanni LucaCeresolidRAMES investigators
doi : 10.1016/S1470-2045(21)00666-5
Volume 22, Issue 12, December 2021, Page e533
SABR for operable stage I non-small-cell lung cancer: comparison to surgery
TairoKashiharaa
doi : 10.1016/S1470-2045(21)00594-5
Volume 22, Issue 12, December 2021, Page e534
SABR for operable stage I non-small-cell lung cancer: comparison to surgery
Meng-SiLuoa
doi : 10.1016/S1470-2045(21)00632-X
Volume 22, Issue 12, December 2021, Page e535
SABR for operable stage I non-small-cell lung cancer: comparison to surgery
JiaqiZhangaLeiLiuaKeZhaoaChaoGuoaShanqingLia
doi : 10.1016/S1470-2045(21)00656-2
Volume 22, Issue 12, December 2021, Page e536
SABR for operable stage I non-small-cell lung cancer: comparison to surgery – Authors' reply
Joe YChangaVivekVermaaLeiFengbJack ARothc
doi : 10.1016/S1470-2045(21)00668-9
Volume 22, Issue 12, December 2021, Pages e537-e538
Correction to Lancet Oncol 2021; 22: 1484–85
doi : 10.1016/S1470-2045(21)00633-1
Volume 22, Issue 12, December 2021, Page e539
Correction to Lancet Oncol 2021; 22: 1497–98
doi : 10.1016/S1470-2045(21)00671-9
Volume 22, Issue 12, December 2021, Page e539
Correction to Lancet Oncol 2021; 22: 1721–31
doi : 10.1016/S1470-2045(21)00672-0
Volume 22, Issue 12, December 2021, Page e539
Annual Congress of the European Association of Nuclear Medicine 2021
Flávia OliveiraGeraldes
doi : 10.1016/S1470-2045(21)00634-3
Volume 22, Issue 12, December 2021, Page 1655
Roadmap to deal with toxic chemicals in the USA
ManjulikaDas
doi : 10.1016/S1470-2045(21)00635-5
Volume 22, Issue 12, December 2021, Page 1656
2021 ASTRO annual meeting
KatherineGourd
doi : 10.1016/S1470-2045(21)00643-4
Volume 22, Issue 12, December 2021, Page 1657
Tobacco industry influence during the COVID-19 pandemic
Talha KhanBurki
doi : 10.1016/S1470-2045(21)00644-6
Volume 22, Issue 12, December 2021, Page 1658
Impact of the UK Budget on cancer care and research
ElizabethGourd
doi : 10.1016/S1470-2045(21)00645-8
Volume 22, Issue 12, December 2021, Page 1659
Fuel shortage affects cancer care in Haiti
ManjulikaDas
doi : 10.1016/S1470-2045(21)00646-X
Volume 22, Issue 12, December 2021, Page 1660
Carcinogenicity of 1,1,1-trichloroethane and four other industrial chemicals
doi : 10.1016/S1470-2045(21)00659-8
Volume 22, Issue 12, December 2021, Pages 1661-1662
New coalition to harmonise USA–China cancer research and care
AshrayGunjur
doi : 10.1016/S1470-2045(21)00670-7
Volume 22, Issue 12, December 2021, Page e540
Cancer care for displaced children in Lebanon
RayaSaabaKhaledGhanembSimaJehac
doi : 10.1016/S1470-2045(21)00631-8
Volume 22, Issue 12, December 2021, Pages 1663-1664
Cancer care for displaced children from Venezuela
Monika LMetzgeraAugustoPereirabPatríciaLoggettoaCarlosRodriguez-Galindoa
doi : 10.1016/S1470-2045(21)00642-2
Volume 22, Issue 12, December 2021, Pages 1665-1666
Cancer care for children in the Gaza Strip
ZeenaSalmanaMahmoudShbairbMomenZeineddinbTalhaBaloushacIbrahimQaddoumiaCarlosRodriguez-Galindoa
doi : 10.1016/S1470-2045(21)00655-0
Volume 22, Issue 12, December 2021, Pages 1667-1668
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study
David JPinatoPhDabProfJosepTaberneroPhDgProfMarkBowerPhDjkLorenzaScottiPhDeMeeraPatelBScaEmelineColombaMDlSaoirseDollyPhDmAngelaLoizidouMDnProfJohnChesterPhDopUmaMukherjeePhDqAlbertoZambelliMDrAlessiaDalla PriaMDjkJuanAguilar-CompanyMDgDiegoOttavianiPhDsAmaniChowdhuryMDsEveMerryMDsRamonSalazarPhDtAlexiaBertuzziMDvJoanBrunetPhDwMatteoLambertiniPhDxyMarcoTagliamentoMDxyAnnaPousMDwAilsaSita-LumsdenPhDmKrishnieSrikandarajahMBBSmJohannColombaMDlFannyPommeretMDlEliaSeguíMDzProfDanieleGeneraliPhDabacSalvatoreGrisantiPhDadaeProfPaoloPedrazzoliMDafGianpieroRizzoMDaeMichelaLibertiniMDagCharlotteMossMResahJoanne SEvansMPhilaBethRussellPhDahProfNadiaHarbeckPhDaiBrunoVincenziPhDajFedericaBielloMDbfRossellaBertulliMDakRaquelLiñanMDwSabrinaRossiMDvMaria CarmenCarmona-GarcíaMDwCarloTondiniMDrLauraFoxMDhAliceBaggiMDadaeVittoriaFotiaMDrAlessandroParisiMDalGiamperoPorzioMDamMaristellaSaponaraMDanClaudia AndreaCruzMDzDavidGarcía-IllescasMDgEudaldFelipMDwAriadnaRoqué LloverasMDwRachelSharkeyRNjkElisaRoldánMDgRoxanaReyesMDzIrinaEarnshawMBCHBsDanielaFerrantePhDeJavierMarco-HernándezMDaaIsabelRuiz-CampsPhDiGianlucaGaidanoMDdfAndreaPatriarcaMDdfRiccardoBrunaMDdfAnnaSuredaPhDuClaraMartinez-VilaMDaoAnaSanchez de TorreMDapLucaCantiniMDaqMarcoFilettiMDarLorenzaRimassaMDvasLorenzoChiudinelliMDrMichelaFranchiMDrMarcoKrengliMDcfProfArmandoSantoroMDvasProfAleixPratPhDzatProfMiekeVan HemelrijckPhDahNikolaosDiamantisPhDqThomasNewsom-DavisPhDjkAlessandraGennariPhDbfAlessioCortelliniMDaamon behalf of the
doi : 10.1016/S1470-2045(21)00573-8
Volume 22, Issue 12, December 2021, Pages 1669-1680
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial
Sjoukje FOostingMDa*Astrid A Mvan der VeldtMDde*Corine HGeurtsvanKesselMDfRudolf S NFehrmannMDaRob Svan BinnendijkPhDhProfAnne-Marie CDingemansMDgProfEgbert FSmitMDjT Jeroen NHiltermannMDbGercoden HartogPhDhMathildaJalvingMDaTatjana TWestphaliArkajyotiBhattacharyaaMariekevan der HeidenPhDcProfGuus FRimmelzwaanPhDmPiaKvistborgPhDkProfChristian UBlankMDlProfMarion P GKoopmansPhDfProfAnke L WHuckriedePhDcProfCecile A C Mvan ElsPhDhnNynke YRotsPhDhProfDebbievan BaarlePhDchProfJohn B A GHaanenMDlProfElisabeth G Ede VriesMDa
doi : 10.1016/S1470-2045(21)00574-X
Volume 22, Issue 12, December 2021, Pages 1681-1691
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
ProfHussein ATawbiMDaProfPeter AForsythMDbProfF StephenHodiMDcAlain PAlgaziMDdOmidHamidMDeProfChristopher DLaoMDfStergios JMoschosMDgProfMichael BAtkinsMDhKarlLewisMDiMichael APostowMDjReena PThomasMDkProfJohnGlaspyMDlSekwonJangMDmNikhil IKhushalaniMDnAnna CPavlickDOoProfMarc SErnstoffMDpProfDavid AReardonMDqRaginiKudchadkarMDrProfAhmadTarhiniMDsCarolineChungMDaCoreyRitchingsPharmDtPiyushDuraniMDtMargaritaAskelsonMSctProfIgorPuzanovMDuProfKim AMargolinMDv
doi : 10.1016/S1470-2045(21)00545-3
Volume 22, Issue 12, December 2021, Pages 1692-1704
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
FrancescaGayPhDa*ProfPellegrinoMustoMDb*DeliaRota-ScalabriniMDcLucaBertaminiMDaAngeloBelottiMDdMonicaGalliPhDeMassimoOffidaniMDfElenaZamagniPhDgAntonioLeddaMDhMariellaGrassoMDiStelvioBallantiMDjAntonioSpadanoMDkMicheleCeaMDlFrancescaPatriarcaPhDmMattiaD'AgostinoMDaAndreaCapraMScEngaNicolaGiulianiPhDnPaolode FabritiisMDoSaraAquinoPhDpAngeloPalmasMDqBarbaraGamberiMDrRenatoZambelloMDsMaria TeresaPetrucciMDtProfPaoloCorradiniMDuProfMicheleCavoMDgProfMarioBoccadoroMDa
doi : 10.1016/S1470-2045(21)00535-0
Volume 22, Issue 12, December 2021, Pages 1705-1720
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
SusanaBanerjeePhDaProfKathleen NMooreMDbProfNicolettaColomboPhDcProfGiovanniScambiaMDdProfByoung-GieKimMDeProfAnaOakninMDfProfMichaelFriedlanderMDgAllaLisyanskayaMDhAnneFloquetMDiAlexandraLearyMDjProfGabe SSonkeMDkProfCharlieGourleyPhDlProfAmitOzaMDmAntonioGonzález-MartínMDnProfCarolAghajanianMDoWilliam HBradleyMDpEileenHolmesPhDqElizabeth SLoweMDrProfPaulDiSilvestroMDs
doi : 10.1016/S1470-2045(21)00531-3
Volume 22, Issue 12, December 2021, Pages 1721-1731
Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial
ChadTangMDacd†PavlosMsaouelMDbc†KiekoHaraMDcProfHaesunChoiMDeVenusLeMPHaAmishi YShahMDbJenniferWangMDbProfEricJonaschMDbProfSeungtaekChoiMDaQuynh-nhuNguyenMDaProfPrajnanDasaSurendraPrajapatiPhDfZhiqianYuPhDfKhajaKhanBScStevenPowellMScRaviMurthyMDgProfKanishkaSircarMDchProfNizar MTannirMDb
doi : 10.1016/S1470-2045(21)00528-3
Volume 22, Issue 12, December 2021, Pages 1732-1739
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
Nehal JLakhaniMDaProfLaura Q MChowMDbcJustin FGainorMDdProfPatriciaLoRussoDOeProfKeun-WookLeeMDfProfHyun CheolChungMDgProfJeeyunLeeMDhProfYung-JueBangMDiProfFrank StephenHodiMDjProfWon SeogKimMDhRafaelSantana-DavilaMDbPhilipFanningPhDkPierreSquiffletMSlFengJinPhDkTracy CKuoPhDkHong IWanPhDkJaumePonsPhDkSophia SRandolphMDkProfWells AMessersmithMDm
doi : 10.1016/S1470-2045(21)00584-2
Volume 22, Issue 12, December 2021, Pages 1740-1751
177Lu-Dotatate plus long-acting octreotide versus high?dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
ProfJonathan RStrosbergMDaProfMartyn ECaplinMDbPamela LKunzMDcProfPhilippe BRuszniewskiMDdLisaBodeiMDeAndrewHendifarMDfErikMittraMDgEdward MWolinMDhJames CYaoMDiProfMarianne EPavelMDjEnriqueGrandeMDkProfEricVan CutsemPhDlEttoreSeregniMDmHugoDuarteMDnGermoGerickeMDoAmyBartalottaMApMaurizio FMarianiMDoArnaudDemangeMScoSakirMutevelicMDoProfEric PKrenningMDqon behalf of the
doi : 10.1016/S1470-2045(21)00572-6
Volume 22, Issue 12, December 2021, Pages 1752-1763
Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study
ProfMatthiasFischerMDaProfLucasMorenoMDbcDavid SZieglerMDdeLynley VMarshallMDfProfC MichelZwaanMDgProfMeredith SIrwinMDhMichelaCasanovaMDiConstantinoSabadoMDcBeateWulffMDjMarioStegertMDkLuojunWangMDmFelipe KHurtadoPhDmFabriceBranleMDlBirgitGeoergerMDn†ProfJohannes HSchulteMDopq†
doi : 10.1016/S1470-2045(21)00536-2
Volume 22, Issue 12, December 2021, Pages 1764-1776
Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study
David CQianMDaTroyKleberMSCRaBriannaBrammerBSdKaren MXuMDaJeffrey MSwitchenkoPhDeJames RJanopaul-NaylorMDaJimZhongMDaMelinda LYushakMDbProfR DonaldHarveyPharmDbChrystal MPaulosPhDcProfDavid HLawsonMDbMohammad KKhanMDaRagini RKudchadkarMDbZachary SBuchwaldMDaf
doi : 10.1016/S1470-2045(21)00546-5
Volume 22, Issue 12, December 2021, Pages 1777-1786
Cancer incidence, patterns, and genotype–phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study
Kelvin Césarde AndradePhDa†Payal PKhinchaMBBSa†Jessica NHattonMSaMegan NFroneMSaTaliaWegman-OstroskyPhDabPhuong LMaiMDacAna FBestPhDdSharon ASavageMDa
doi : 10.1016/S1470-2045(21)00580-5
Volume 22, Issue 12, December 2021, Pages 1787-1798
Financial toxicity in cancer care in India: a systematic review
Jeffrey MathewBobyaSenthilRajappaDMbAjuMathewDMc
doi : 10.1016/S1470-2045(21)00468-X
Volume 22, Issue 12, December 2021, Pages e541-e549
Immunotherapy for cancer treatment during pregnancy
Jessica S WBorgersMDa*Joosje HHeimovaaraMDd*ProfElyceCardonickPhDeProfDaanDierickxPhDcfMatteoLambertiniPhDghProfJohn B A GHaanenPhDaProfFrédéricAmantPhDbd
doi : 10.1016/S1470-2045(21)00525-8
Volume 22, Issue 12, December 2021, Pages e550-e561
Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromes
ProfJulietteThariatMDabFrancoisChevalierPhDcdDanielOrbachMDeLucOllivierMDabPierre-YvesMarcyMDfNadegeCorradiniMDgArnaudBeddokMDhNicolasForayPhDiGaelleBougeardPhDjk
doi : 10.1016/S1470-2045(21)00425-3
Volume 22, Issue 12, December 2021, Pages e562-e574
Diplopia, proptosis, and the pancreas
Anupam KumarSinghDMaYugankiKushMDb
doi : 10.1016/S1470-2045(21)00592-1
Volume 22, Issue 12, December 2021, Page e575
